Insider Trading February 9, 2026

Monro CEO Buys $251K of Company Stock After Mixed Q3 Results

Peter D. Fitzsimmons purchases 12,750 shares as Monro posts an EPS beat but narrowly misses revenue estimates

By Sofia Navarro MNRO
Monro CEO Buys $251K of Company Stock After Mixed Q3 Results
MNRO

Monro, Inc.'s CEO, Peter D. Fitzsimmons, acquired 12,750 shares of the company's common stock on February 5, 2026, for roughly $250,879. The purchase increased his direct holdings to 112,033 shares. Separately, Monro reported third-quarter fiscal 2026 results with earnings per share of $0.16—above analysts' $0.13 estimate—while revenue of $293.4 million fell short of the $295.2 million analysts expected. The stock declined in pre-market trading following the release.

Key Points

  • Monro CEO Peter D. Fitzsimmons purchased 12,750 shares on February 5, 2026 at $19.6768 per share, totaling about $250,879 and raising his direct holdings to 112,033 shares.
  • Monro reported Q3 fiscal 2026 EPS of $0.16, beating analyst expectations of $0.13, while revenue of $293.4 million narrowly missed the $295.2 million estimate.
  • Despite the EPS beat, Monro's stock fell in pre-market trading, reflecting the mixed nature of the quarter's results and investor response.

Insider purchase confirmed

Peter D. Fitzsimmons, who serves as President and Chief Executive Officer of MONRO, INC. (NASDAQ: MNRO), bought 12,750 shares of the company's common stock on February 5, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were acquired at a per-share price of $19.6768, producing a total outlay of approximately $250,879.

After the transaction, Fitzsimmons directly holds 112,033 shares of Monro, Inc.


Quarterly results

Monro reported its third-quarter results for fiscal year 2026, posting earnings per share of $0.16. That figure exceeded analyst expectations, which were set at $0.13 per share. Revenue for the quarter was announced at $293.4 million, narrowly missing the analyst consensus of $295.2 million.

Despite the EPS beat, shares of Monro declined in pre-market trading following the release of the results. The company’s mixed performance of stronger-than-expected EPS alongside slightly lower-than-expected revenue was noted in reporting on the quarter.


Context and immediate takeaways

The insider purchase and the company's latest quarterly print together provide investors with updated information on both executive activity and Monro's recent operating performance. The EPS outcome surpassed forecasts, while revenue came in a touch below what analysts had projected. Market reaction ahead of the open reflected those mixed signals.

Limitations

Details available in the filings and the earnings release are limited to the transaction amount, the share counts, and the headline earnings and revenue figures. No additional commentary or forward-looking statements from management are included in the information provided here.


Data summary

  • Insider transaction: 12,750 shares purchased on February 5, 2026 at $19.6768 per share; total approximately $250,879.
  • Post-transaction direct ownership for Fitzsimmons: 112,033 shares.
  • Q3 FY2026 EPS: $0.16 (analyst estimate: $0.13).
  • Q3 FY2026 Revenue: $293.4 million (analyst estimate: $295.2 million).
  • Immediate market reaction: decline in pre-market trading.

Risks

  • Revenue for Q3 FY2026 fell short of analyst expectations, introducing uncertainty about top-line trends.
  • The stock's decline in pre-market trading signals potential market sensitivity to near-term performance indicators.
  • Available information is limited to the transaction details and headline quarterly figures; lack of additional management commentary leaves aspects of future performance unclear.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026